Purine isosters in design and development of novel xanthin oxidase inhibitors

Abstract

This research focuses on the discovery of novel inhibitors of the enzyme xanthine oxidase to assist in the treatment of hyperuricemia and gout. Four different libraries of compounds with a total of 95 molecules were synthesized, purified, characterized and tested in-vitro, with additional molecular docking conducted to rationalize binding interactions. The most active compound was more than 900 times more effective in-vitro than Allopurinol, the current drug of first choice in the market.